Payment overview · 2025
General Payments
$288.84
14 reported records · 8 companies
Healthcare provider profile · identity verified
Muhammad Hanif, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1013999036
Verified facts
What the public records show
CMS Open Payments records show Muhammad Hanif, M.D. received $288.84 in general payments during 2025 across 14 reported records.
SCPHARMACEUTICALS INC. accounted for 29.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $84.13 | 29.1% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $60.74 | 21.0% | 3 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $30.76 | 10.7% | 2 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $26.79 | 9.3% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $25.56 | 8.8% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.54 | 8.2% | 1 | 2025 |
| Calliditas Therapeutics US Inc. | Unresolved — no canonical attribution shown | $21.86 | 7.6% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $15.46 | 5.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $288.84 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $84.13 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.55 | 2 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $30.76 | 2 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $26.79 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $25.56 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $23.54 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $22.19 | 1 | 2025 |
Source payment records
|
|||||
| TARPEYO Normalized: tarpeyo |
Drug | Calliditas Therapeutics US Inc. | $21.86 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $15.46 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 82 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
82 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 47 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 311 | 98 |
| Levothyroxine Sodium | Levothyroxine Sodium | 219 | 46 |
| Amlodipine Besylate | Amlodipine Besylate | 187 | 62 |
| Prednisone | Prednisone | 160 | 83 |
| Furosemide | Furosemide | 138 | 54 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 132 | 56 |
| Pantoprazole Sodium | Pantoprazole Sodium | 131 | 70 |
| Eliquis | Apixaban | 127 | 47 |
| Gabapentin | Gabapentin | 122 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 110 | 38 |
| Xarelto | Rivaroxaban | 109 | 17 |
| Lisinopril | Lisinopril | 103 | 32 |
| Carvedilol | Carvedilol | 101 | 50 |
| Losartan Potassium | Losartan Potassium | 100 | 29 |
| Potassium Chloride | Potassium Chloride | 100 | 35 |
| Metformin Hcl | Metformin Hcl | 96 | 27 |
| Donepezil Hcl | Donepezil Hcl | 86 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 40 |
| Mirtazapine | Mirtazapine | 85 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 82 | 32 |
| Sertraline Hcl | Sertraline Hcl | 79 | 21 |
| Omeprazole | Omeprazole | 76 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 70 | 32 |
| Nifedipine Er | Nifedipine | 67 | 36 |
| Famotidine | Famotidine | 65 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 60 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 53 | 44 |
| Simvastatin | Simvastatin | 48 | 12 |
| Tramadol Hcl | Tramadol Hcl | 48 | 20 |
| Finasteride | Finasteride | 47 | 12 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 47 | 11 |
| Trazodone Hcl | Trazodone Hcl | 47 | 19 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 46 | 25 |
| Alprazolam | Alprazolam | 43 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 43 | 16 |
| Montelukast Sodium | Montelukast Sodium | 42 | 19 |
| Lactulose | Lactulose | 40 | 18 |
| Azithromycin | Azithromycin | 39 | 32 |
| Cefdinir | Cefdinir | 38 | 33 |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Meloxicam | Meloxicam | 34 | 15 |
| Allopurinol | Allopurinol | 33 | 16 |
| Duloxetine Hcl | Duloxetine Hcl | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 31 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 30 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 30 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 29 | 11 |
| Glipizide | Glipizide | 28 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Scopolamine | Scopolamine | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Pregabalin | Pregabalin | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Levetiracetam | Levetiracetam | 24 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 24 | suppressed |
| Budesonide | Budesonide | 23 | suppressed |
| Bupropion Xl | Bupropion Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Cephalexin | Cephalexin | 21 | 20 |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 21 | 14 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 21 | 11 |
| Spironolactone | Spironolactone | 21 | 12 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 20 | suppressed |
| Lorazepam | Lorazepam | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | 14 |
| Levofloxacin | Levofloxacin | 19 | 16 |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 18 |
| Ezetimibe | Ezetimibe | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 16 |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 14 |
| Ondansetron Odt | Ondansetron | 18 | 16 |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Acetazolamide | Acetazolamide | 17 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 17 | 14 |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 16 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Jardiance | Empagliflozin | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 15 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 15 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 15 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Clonidine | Clonidine | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Brilinta | Ticagrelor | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | 11 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rebif | Interferon Beta-1a/Albumin | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Metronidazole | Metronidazole | 11 | 11 |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Yupelri | Revefenacin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $288.84 · 14 records | SCPHARMACEUTICALS INC. | ELIQUIS, FUROSCIX, Fetroja, Leqembi, NUCALA, NURTEC ODT, NUZYRA, OPSUMIT, TARPEYO, TRELEGY ELLIPTA, UPTRAVI | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error